EPZM Shares Outstanding History



Below is a table of the EPZM shares outstanding history going back to 5/31/2013:

Date EPZM Shares Outstanding
5/31/201326.79M
7/26/201328.42M
10/18/201328.42M
2/21/201432.75M
5/5/201433.15M
8/8/201433.58M
10/31/201434.16M
3/6/201534.47M
4/24/201541.20M
7/31/201541.33M
10/30/201541.70M
3/1/201657.21M
5/2/201657.22M
8/3/201657.96M
10/28/201658.01M
3/1/201758.25M
5/1/201758.36M
8/1/201758.47M
10/25/201769.28M
3/1/201869.44M
5/1/201869.49M
7/30/201869.50M
10/31/201879.17M
2/19/201979.21M
4/30/201990.83M
7/31/201991.04M
10/25/201991.07M
2/19/2020100.77M
4/30/2020101.06M
7/30/2020101.48M
10/30/2020101.58M
2/18/2021101.79M
4/30/2021101.98M
8/4/2021102.25M
11/4/2021103.90M
2/24/2022164.48M
5/4/2022164.87M
8/5/2022168.36M

Also see: EPZM Market Cap History
EPZM YTD Return
EPZM Historical Shares Outstanding:
+22.15% CAGR
EPZM Historical Shares Outstanding: +22.15% CAGR

Mouse over chart for data details
5/31/2013 ...8/5/2022
Epizyme is a biopharmaceutical company that is focused on rewriting treatment for people with cancer and other serious diseases through the discovery, development, and commercialization of epigenetic medicines. Co. has one approved product, TAZVERIK (tazemetostat), which was granted approval by the U.S. Food and Drug Administration (FDA) for epithelioid sarcoma (ES), and follicular lymphoma (FL). The FDA has granted approval of TAZVERIK (tazemetostat), an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced ES not eligible for complete resection. We show 38 historical shares outstanding datapoints in our coverage of EPZM's shares outstanding history.

Understanding the changing numbers of EPZM shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like EPZM versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching EPZM by allowing them to research EPZM shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree EPZM Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Epizyme (EPZM) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

EQ Shares Outstanding History
ERAS Shares Outstanding History
ERNA Shares Outstanding History
ESPR Shares Outstanding History
ESRX Shares Outstanding History
ETNB Shares Outstanding History
ETON Shares Outstanding History
ETTX Shares Outstanding History
EVFM Shares Outstanding History
EVHC Shares Outstanding History
More Healthcare companies »

 

EPZM Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.